Maria G. C.
- Country
- Germany
- Department
- Medizinische Klinik und Poliklinik I
Research Overview
- Phase III Study of Rilvegostomig plus Combination Chemotherapy versus Durvalumab plus Combination Chemotherapy in Patients with Advanced Biliary Tract Cancer
- Safety and Efficacy of PF-08634404 as Monotherapy and in Combination with Ipilimumab in Adults with Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma
- Phase III Randomized Trial of AZD0901 with Capecitabine ± Rilvegostomig in First‑Line Claudin‑18.2‑Positive HER2‑Negative Advanced Gastric, GEJ or Esophageal Adenocarcinoma
Data & Insights
Has run more than one trial at 147 of 281 partner sites.
Specializations
Liver Cancer Research
Specializes in advanced therapeutic approaches for hepatocellular carcinoma (HCC), investigating various treatment combinations including immunotherapy and targeted interventions.
- Locoregional HCC Treatment
- Immunotherapy Combinations
- Transarterial Chemoembolization
Focuses on developing treatment strategies for both resectable and non-resectable liver cancers.
Biliary Tract Oncology
Conducts research in cholangiocarcinoma and related biliary tract malignancies, exploring novel therapeutic approaches.
- Extrahepatic Cholangiocarcinoma
- Adjuvant Therapy Strategies
- Targeted Molecular Treatments
Investigates innovative combination therapies including immunotherapy and radiofrequency ablation.
Gastrointestinal Cancer Innovation
Leads research in gastroesophageal junction adenocarcinoma and other advanced gastrointestinal malignancies.
- Anal Canal Carcinoma
- Neoadjuvant Therapy
- Multimodal Treatment Approaches
Explores combined treatment modalities including radiochemotherapy and targeted biological agents.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.